To include your compound in the COVID-19 Resource Center, submit it here.

Spectrum completes enrollment in Phase III trial of Rolontis for chemotherapy-induced neutropenia

Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) completed enrollment of 405 patients in the Phase III ADVANCE trial of Rolontis eflapegrastim to treat chemotherapy-induced neutropenia.

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE